Makers of MyClyns® Secure Additional Series A Financing
Blue Chip Venture Company leads Capital Infusion into Union Springs Pharmaceuticals
Union, KY, August 21, 2009 --(PR.com)-- The makers of MyClyns®, Union Springs Pharmaceuticals, has received an additional round of Series A Financing by several investors including Cincinnati-based Blue Chip Venture Company. The round totaled in excess of $5 million. Union Springs Pharmaceuticals developed the Clyns Brand germ defense products initially designed for first responders. According to chairman and founder Roger Griggs, the infusion of cash will enable the company to ramp up the sales and marketing organization to take advantage of the tremendous interest in the company’s products and expand its reach into the healthcare and consumer market segments.
The Clyns Brands products that are marketed by Union Springs Pharmaceuticals gained mainstream popularity after recent H1N1 swine flu breakouts. Both the T-5000 respirator and the MyClyns personal protection spray have already proven to be significant assets to public safety officials, military, corrections, and EMS personnel throughout the United States. Expansion into Canadian and European first responder and consumer markets poises the Northern Kentucky-based company for rapid growth.
“We have been fortunate to raise capital from multiple funding sources over the years, and it is particularly rewarding to have several local investors join Blue Chip, as well as several investors from outside of the region, to form our cornerstone of participants” Griggs said.
The Clyns Brands product line includes the only germ-fighting spray for the eyes, mouth, nose, and open wounds. Independent laboratory tests have shown a 99% reduction of more than 60 pathogens, including MRSA, within 30 seconds after use. Union Springs Pharmaceuticals also markets a line of P95 disposable respirators with Triosyn® antimicrobial technology that are effective against numerous pathogens including the flu virus, bacteria, spores, fungi and protozoa.
Blue Chip Managing Director Jack Wyant explained that his organization partners with companies that have strong, experienced executive teams that are “highly ethical, passionate and strategic, and have a proven track record of success. We have found this to be so in our past successes with Roger Griggs and are highly optimistic about the prospects for the future of this organization, its products and its people.”
About Union Springs Pharmaceuticals
Union Springs Pharmaceuticals, LLC specializes in providing innovative infection control products for the EMS, fire, law enforcement, corrections, military, government, healthcare, and consumer markets. Union Springs Pharmaceuticals offers personal and environmental exposure response products including, MyClyns, the revolutionary germ-fighting spray that can be applied into the eyes, mouth, nose, and open wounds. Union Springs also offers the T-5000 series disposable respirators, the only disposable respirator coated with a broad spectrum, EPA-registered antimicrobial (Triosyn®) to help protect against small airborne threats. The company has plans to launch several complimentary new technologies into the marketplace by the end of 2009. More information can be accessed at www.ClynsBrands.com or by calling 859.384.4029.
About Blue Chip Venture Company
Blue Chip Venture Company is a Cincinnati-based venture capital firm with $600 million under management, investments in over 100 companies, and offices in Indianapolis and New York. Blue Chip invests in privately-owned, early stage, high growth companies in the healthcare, media and marketing and software industries. More information about Blue Chip Venture Company can be found at www.bcvc.com.
###
The Clyns Brands products that are marketed by Union Springs Pharmaceuticals gained mainstream popularity after recent H1N1 swine flu breakouts. Both the T-5000 respirator and the MyClyns personal protection spray have already proven to be significant assets to public safety officials, military, corrections, and EMS personnel throughout the United States. Expansion into Canadian and European first responder and consumer markets poises the Northern Kentucky-based company for rapid growth.
“We have been fortunate to raise capital from multiple funding sources over the years, and it is particularly rewarding to have several local investors join Blue Chip, as well as several investors from outside of the region, to form our cornerstone of participants” Griggs said.
The Clyns Brands product line includes the only germ-fighting spray for the eyes, mouth, nose, and open wounds. Independent laboratory tests have shown a 99% reduction of more than 60 pathogens, including MRSA, within 30 seconds after use. Union Springs Pharmaceuticals also markets a line of P95 disposable respirators with Triosyn® antimicrobial technology that are effective against numerous pathogens including the flu virus, bacteria, spores, fungi and protozoa.
Blue Chip Managing Director Jack Wyant explained that his organization partners with companies that have strong, experienced executive teams that are “highly ethical, passionate and strategic, and have a proven track record of success. We have found this to be so in our past successes with Roger Griggs and are highly optimistic about the prospects for the future of this organization, its products and its people.”
About Union Springs Pharmaceuticals
Union Springs Pharmaceuticals, LLC specializes in providing innovative infection control products for the EMS, fire, law enforcement, corrections, military, government, healthcare, and consumer markets. Union Springs Pharmaceuticals offers personal and environmental exposure response products including, MyClyns, the revolutionary germ-fighting spray that can be applied into the eyes, mouth, nose, and open wounds. Union Springs also offers the T-5000 series disposable respirators, the only disposable respirator coated with a broad spectrum, EPA-registered antimicrobial (Triosyn®) to help protect against small airborne threats. The company has plans to launch several complimentary new technologies into the marketplace by the end of 2009. More information can be accessed at www.ClynsBrands.com or by calling 859.384.4029.
About Blue Chip Venture Company
Blue Chip Venture Company is a Cincinnati-based venture capital firm with $600 million under management, investments in over 100 companies, and offices in Indianapolis and New York. Blue Chip invests in privately-owned, early stage, high growth companies in the healthcare, media and marketing and software industries. More information about Blue Chip Venture Company can be found at www.bcvc.com.
###
Contact
Union Springs Pharmaceuticals
Marisa Minor
859-384-4029
uspharma.com
Marisa Minor
859-384-4029
uspharma.com
Contact
Categories